Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Safety Study of BXQ-350 Administered as a Single Agent by Intravenous Infusion in Children and Young Adults With Relapsed Solid Tumors, Including Recurrent Malignant Brain Tumors

NCT03967093 is registered in ClinicalTrials.gov with Bexion Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03967093
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03967093 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Safety Study of BXQ-350 Administered as a Single Agent by Intravenous Infusion in Children and Young Adults With Relapsed Solid Tumors, Including Recurrent Malignant Brain Tumors
Lead sponsor
Bexion Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
April 15, 2019
Completion date
January 17, 2020
Enrollment
9 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms